We previously reported the deubiquitinatingactivity of USP44 and subsequent EZH2 protein stabilization in prostate cancer cellsand suggested that targeting USP44 might be an efficient anticancer strategy forEZH2-dependent cancers irrespective of the enzymatic activity of EZH2 (Park et al., 2019). This evidence concerns the gene EZH2 and cancer.